SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-116005
Filing Date
2023-11-09
Accepted
2023-11-09 07:42:50
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330254d1_8k.htm   iXBRL 8-K 25713
2 EXHIBIT 99.1 tm2330254d1_ex99-1.htm EX-99.1 118480
6 GRAPHIC tm2330254d1_ex99-1img001.jpg GRAPHIC 10370
  Complete submission text file 0001104659-23-116005.txt   344192

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA carm-20231109.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20231109_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20231109_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2330254d1_8k_htm.xml XML 3316
Mailing Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 262025616 | State of Incorp.: PA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 231390102
SIC: 2834 Pharmaceutical Preparations